Skip to main content
. 2019 Aug;8(4):1242–1248. doi: 10.21037/tcr.2019.07.10

Figure 3.

Figure 3

Sensitivity and specificity of FR+CTC and other tumor biomarkers. Bar charts showing (A) the sensitivity of FR+CTC in the diagnosis of lung cancer and stage I lung cancer; and (B) the specificity of FR+CTC in the diagnosis of lung cancer. CEA, carcinoembryonic antigen; CYFRA21-1, cytokeratin fragment 19; FR+CTC, folate receptor-positive circulating tumor cell; NSE, neuron-specific enolase.